Latest & greatest articles for copd exacerbations

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd exacerbations or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd exacerbations and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd exacerbations

1. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline

Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline Jadwiga A. Wedzicha (ERS co-chair) , Marc Miravitlles , John R. Hurst , Peter M.A (...) obstructive pulmonary disease (COPD) exacerbations. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of COPD experts. After considering

2017 European Respiratory Society

2. The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation

The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page

2018 NIHR HTA programme

4. Prevention of Acute Exacerbations of COPD

Prevention of Acute Exacerbations of COPD 894 Evidence-Based Medicine [ 147#4 CHEST APRIL 2015 ] P r e v en tio n o f A c u t e Exacerba tio n s o f C O PD American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP ; Pat G. Camp (...) the rest of the world. An exacerbation of COPD (periodic escalations of symptoms of cough, dyspnea, and sputum production) is a major contributor to worsening lung function, impairment in quality of life, need for urgent care or hospitalization, and cost of care in COPD. Research conducted over the past decade has contributed much to our current understanding of the pathogenesis and treatment of COPD. Additionally, an evolving literature has accumu- lated about the prevention of acute exacerbations

2015 American College of Chest Physicians

5. Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations?

Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do antibiotics improve outcomes for patients hospitalized with COPD exacerbations? View/ Open Date 2012-09 (...) Format Metadata Abstract Antibiotic use reduced mortality and treatment failure in patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (COPD) (strength of recommendation [SOR]: A, systematic reviews of randomized controlled trials [RCTs]). Giving antibiotics early to hospitalized patients decreased the need for later ventilation and readmission within 30 days for exacerbation of COPD (SOR: B, a retrospective cohort study). URI Citation Journal of Family Practice

2018 Clinical Inquiries

6. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies (Full text)

Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies El Moussaoui R, Roede B M, Speelman P, Bresser P, Prins J M, Bossuyt P M CRD summary The authors concluded (...) (COPD) or chronic bronchitis. Searching The following databases were searched from inception to July 2006: the Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. Search terms were reported. The reference lists of included studies were handsearched. The search was restricted to studies published in English. Study selection Double-blinded randomised controlled trials (RCTs) of antibiotics for treating acute exacerbation of clinically diagnosed COPD, chronic bronchitis or pulmonary

2008 DARE. PubMed

7. Should you consider antibiotics for exacerbations of mild COPD?

Should you consider antibiotics for exacerbations of mild COPD? Should you consider antibiotics for exacerbations of mild COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Should you consider antibiotics for exacerbations of mild COPD? View/ Open Date 2014-04 Format Metadata Abstract Consider antibiotics (...) for patients with exacerbations of mild to moderate chronic obstructive pulmonary disease (COPD). URI Part of Citation Journal of Family Practice, 64(4): 2014: E11-E13 Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2014 PURLS

8. COPD exacerbations

COPD exacerbations Top results for copd exacerbations - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for copd exacerbations The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many

2018 Trip Latest and Greatest

9. Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality

Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality BestBets: Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption with no increase in rates of treatment failure or mortality Use of a procalcitonin algorithim to guide antimicrobial therapy in COPD exacerbations can reduce antibiotic consumption (...) of chronic obstructive pulmonary disease (COPD)] can [use of a procalcitonin algorithm compared to physician gestalt] result in [lower rates of antibiotic consumption with no adverse effects] Clinical Scenario A 78 year old female presents to your emergency department reporting increased wheezing over the last 24 hours. She reports a mildly productive cough and denies fever. A chest x-ray reveals no clear evidence of pneumonia. In addition to therapy for what you believe is a COPD exacerbation, you

2015 BestBETS

10. 2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of COPD

2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of COPD ONLINE FIRST This is an Online First, unedited version of this article. The final, edited version will appear in a numbered issue of CHEST and may contain substantive changes. We encourage readers to check back for the final article. Online First papers are indexed in PubMed and by search engines, but the information, including the final title and author list, may be updated on final publication. http (...) morbidity costs and $12.4 billion in indirect mortality costs. 9 Exacerbations account for Page 5 of 28 Downloaded From: http://journal.publications.chestnet.org/ on 10/23/2014 5 most of the morbidity, mortality, and costs associated with COPD. The economic burden associated with moderate and severe exacerbations in Canada has been estimated in the range of $646 million to $736 million per annum. 10 This value may be an underestimate given that the prevalence of moderate exacerbations is not well

2014 Canadian Thoracic Society

11. Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD

Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD BestBets: Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD Oral steroids are just as effective as intravenous steroids in acute exacerbations of COPD Report By: Dr Peter Hulme - SHO Search checked by Craig Ferguson - SpR Institution: Trafford General Hospital Date Submitted: 21st June 2008 Date Completed: 3rd May 2011 Last Modified: 3rd June 2011 Status: Green (...) (complete) Three Part Question In [patients with an acute exacerbation of COPD] are [intravenous or oral steroids] better at [reducing length of hospital admission and mortality] Clinical Scenario A 73yr old man with COPD is seen in the Emergency Department. You give him salbutamol and atrovent nebulisers but he remains breathless. You wonder whether giving intravenous or oral steroids would reduce length of hospital stay and his risk of death. Search Strategy EMBASE from 1980 to 2011 Week 08, Ovid

2011 BestBETS

12. Inhaler technique education in elderly patients with asthma or COPD. Impact upon disease control and exacerbations: systematic review

Inhaler technique education in elderly patients with asthma or COPD. Impact upon disease control and exacerbations: systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

13. Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients

Randomised controlled trial: LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients Article Text

2016 Evidence-Based Medicine (Requires free registration)

14. Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis X XIE, M WANG, A SCHAINK (...) , M KRAHN FEBRUARY 2015 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis. February 2015; pp. 1-47 Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness

2015 Health Quality Ontario

15. Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD?

Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? BestBets: Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? Should I use 2.5mg or 5mg Nebulised Salbutamol in Acute Exacerbations of COPD? Report By: Sandeep Rahul Kusre - Senior House Officer Search checked by Jonathan Costello - Consultant A&E Institution: Royal Free Hospital Date Submitted: 4th April 2009 Date Completed: 21st October 2010 Last Modified: 21st October 2010 Status: Green (...) (complete) Three Part Question In [patients admitted with acute exacerbations of COPD] is [5mg nebulised salbutamol superior to 2.5mg nebulised salbutamol] at [improving lung function and reducing length of hospital stay] Clinical Scenario While working a busy nightshift in A&E, you see a patient with an acute exacerbation of COPD. They require bronchodilators & the nurse asks you if you want 2.5mg or 5mg of nebulised salbutamol. You usually administer 5mg however wondered if 2.5mg salbutamol would have

2010 BestBETS

16. Steroids for COPD Exacerbation

Steroids for COPD Exacerbation Steroids for COPD Exacerbation – TheNNTTheNNT Systemic Steroids for Acute COPD Exacerbations 10 for prevented failed treatment In Summary, for those who took the steroids: Benefits in NNT 89.5% saw no benefit 10.5% were helped by not failing treatment 1 out of 10 were helped (preventing failed treatment) Harms in NNT 13.9% harmed by developing adverse drug effects 1 out of 7 were harmed (adverse drug effects) View As: NNT % Source: Efficacy Endpoints: Mortality (...) , Treatment Failure (Lack of resolution, worsening, or death) Harm Endpoints: Adverse Drug Effects Narrative: Chronic obstructive pulmonary disease (COPD), a term that encompasses both patients diagnosed with chronic bronchitis and emphysema, is an obstructive lung disease in many cases caused by years of tobacco smoking. It is thought that patients with COPDexacerbation’ (increased shortness of breath or change in their chronic cough and sputum) may benefit from steroids, presumably by reducing

2010 theNNT

17. Antibiotics for COPD Exacerbation

Antibiotics for COPD Exacerbation Antibiotics for COPD Exacerbation – TheNNTTheNNT Antibiotics for Acute COPD Exacerbations 8 for mortality In Summary, for those who took the antibiotics: Benefits in NNT 88.4% saw no benefit 11.6% were helped by being saved from death 1 in 8 were helped (life saved) 1 in 3 were helped (preventing failed treatment) Harms in NNT 5% were harmed by developing diarrhea 1 in 20 were harmed (diarrhea) View As: NNT % Source: Efficacy Endpoints: Mortality, Treatment (...) Failure (Lack of resolution, worsening, or death) Harm Endpoints: Diarrhea Narrative: Chronic obstructive pulmonary disease (COPD), a term that encompasses both patients diagnosed with chronic bronchitis and emphysema, is an obstructive lung disease, in many cases caused by tobacco smoking. It is thought that patients with COPDexacerbation’ (increased shortness of breath or change in their chronic cough and sputum) may benefit from antibiotics, though the reasons for this are not well elucidated

2010 theNNT

18. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. (Full text)

Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. This document provides clinical recommendations for treatment of chronic obstructive pulmonary disease (COPD) exacerbations.Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach (...) pulmonary rehabilitation in patients having a COPD exacerbation. These recommendations should be reconsidered as new evidence becomes available.Copyright ©ERS 2017.

2017 European Respiratory Journal PubMed

19. Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study (Full text)

Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study Introduction: Chronic obstructive pulmonary disease (COPD) is a heterogeneous illness characterized by persistent airflow obstruction and exacerbations. Patients typically experience a decline in lung function, increasingly impaired health-related quality of life, and high mortality (...) . Poor lung function and exacerbations are associated with an increased risk of cardiovascular (CV) and cerebrovascular events, and approximately 30% of patients with COPD die from CV‑related disease. Treatment with inhaled long-acting bronchodilators, such as long-acting muscarinic antagonists (LAMAs), is recommended; however, some studies have suggested that LAMAs may increase the risk of CV events. As patients with CV and cerebrovascular conditions are often excluded from clinical trials

2018 Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation PubMed

20. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). (Full text)

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Beta-blockers are commonly prescribed for patients with cardiovascular disease. Providers have been wary of treating chronic obstructive pulmonary disease (COPD) patients with beta-blockers due to concern for bronchospasm, but retrospective studies have shown that cardio-selective beta-blockers are safe in COPD and possibly beneficial. However, these benefits may reflect symptom (...) improvements due to the cardiac effects of the medication. The purpose of this study is to evaluate associations between beta-blocker use and both exacerbation rates and longitudinal measures of lung function in two well-characterized COPD cohorts.We retrospectively analyzed 1219 participants with over 180 days of follow up from the STATCOPE trial, which excluded most cardiac comorbidities, and from the placebo arm of the MACRO trial. Primary endpoints were exacerbation rates per person-year and change

2017 Respiratory research PubMed